Treatment guidelines of acute venous thromboembolism. Current status and future perspectives;Indicazioni di terapia della malattia tromboembolica venosa: Attualità e prospettive

Minerva Cardioangiologica

Volumn 51, Issue 4, 2003, Pages 361-371

  Prandoni, P ^a,b   Simioni, P ^a   Pagnan, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Heparin, low molecular weight; Thromboembolism, prevention and control; Venous thrombosis, prevention and control

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; ARDEPARIN; ARGATROBAN; BLOOD CLOTTING FACTOR 5 LEIDEN; COUMARIN; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NADROPARIN; PENTASACCHARIDE; PLASMA PROTEIN; PROTAMINE SULFATE; PROTEIN C; PROTEIN S; PROTHROMBIN; REVIPARIN; STREPTOKINASE; TINZAPARIN; UNINDEXED DRUG; UROKINASE; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COST; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EMBOLECTOMY; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HUMAN; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; QUALITY OF LIFE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN DISEASE;

ACUTE DISEASE; ANTICOAGULANTS; DRUG DESIGN; FORECASTING; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRACTICE GUIDELINES; PULMONARY EMBOLISM; THROMBOEMBOLISM; VENA CAVA FILTERS; VENOUS THROMBOSIS;

EID: 0142214926     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119 Suppl:176-93.
2. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
3. Levine MN, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med 1996;334: 677-81.
4. Aschwanden M, Labs KH, Engel H, Schwab A, Jeanneret C, Mueller-Brand J et al. Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. Thromb Haemost 2001;85:42-6.
5. Partsch H, Blattler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg 2000;32:861-9.
6. de Lissovoy G, Yusen RD, Spiro TE, Krupski WC, Champion AH, Sorensen SV. Cost for inpatient care of venous thrombosis. Arch Intern Med 2000;160:3160-3.
7. Rodger M, Bredeson C, Wells PS, Kearns B, Huebsch LB: Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. CMAJ 1998;159:931-8.
8. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
9. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost 2002;88: 407-14.
10. Prandoni P. Terapia e prevenzione secondaria del-l'embolia polmonare. In: Prandoni P, editor. Terapia e prevenzione della malattia tromboembolica venosa. Padova: Editore Piccin; 2000.p.109-26.
11. Konstantinides S, Gebel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-50.
12. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2000;160:181-8.
13. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-9.
14. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999;130:789-99.
15. Prandoni P. Terapia e prevenzione secondaria della trombosi venosa profonda. In: Prandoni P, editor. Terapia e prevenzione della malattia tromboembolica venosa. Padova: Editore Piccin; 2000.p.43-107.
16. Hommes DW, Bura A, Mazzolai L, Büller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 1992;116:279-84.
17. Prandoni P, Bagatella P, Bernardi E, Girolami B, Rossi L, Scarano L et al. Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Ann Intern Med 1998;129:299-302.
18. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322: 1260-4.
19. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119 Suppl:108-21.
20. Agnelli G, Becattini C, Kirschstein T. Thrombolysis us heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002;162:2537-41.
21. Hull RD, Raskob GE, Hirsh J, Sackett DL. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. JAMA 1984;252:235-9.
22. van der Heijden JF, Hutten BA, Buller HR, Prins MH. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002; (1):CD002001.
23. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
24. Prandoni P. The optimal long term treatment of deep venous thrombosis. Klin Forschung 2002;8:19-20.
25. Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125:1-7.
26. Lensing AWA, Prandoni P, Prins HR, Büller HR. Deep-vein thrombosis. Lancet 1999;353:479-85.
27. Becker DM, Philbrick JT, Selby B. Inferior vena cava filters. Indications, safety, effectiveness. Arch Intern Med 1992;152:1985-94.
28. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998;338:409-15.
29. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity. A phase II evaluation. Circulation 2000;102:2726-31.
30. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombon inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis. J Thromb Haemost 2003;1:41-7.